Product Information
BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE is a generic product labeled by H2-Pharma LLC, priced at $2.4028 per EA under NDC 61269038512. Its NADAC has been published 131 times since Apr 3, 2024.
FDA first approved this application on Sep 28, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDEStrength
140; 125; 125 mg/1; mg/1; mg/1
Manufacturer
H2-Pharma LLCNDC
61269038512
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA050786FDA Approved
9/28/2006
TE Code
AB
On Market Since
7/31/2023
Pharmacological Classes
Price Statistics
The NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has been published 131 times since Apr 3, 2024, and over the history we have for it it has declined 46.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.4028 per EA |
|---|---|
| All-time high | $4.4687 (Apr 10, 2024) |
| All-time low | $2.3760 (Aug 19, 2026) |
| 52-week high | $3.6473 |
| 52-week low | $2.3760 |
| Median price | $3.5583 |
| Average price | $3.4274 |
| Largest weekly change | -22.6% (Jul 17, 2024) |
| Weeks tracked | 131 |
| Tracking since | Apr 3, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
H2-Pharma LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Bismuth class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE, manufactured by H2-Pharma LLC, is $2.4028 per EA (NDC 61269038512), effective Sep 30, 2026.
How has the price of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has declined 46.2%. It has been tracked across 131 weekly CMS publications since Apr 3, 2024.
What are the highest and lowest recorded NADAC prices for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
Since Apr 3, 2024, the NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has ranged from a low of $2.3760 (Aug 19, 2026) to a high of $4.4687 (Apr 10, 2024), with a median of $3.5583 per EA.
Are there cheaper alternatives to BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE (NDC 61269038512) is labeled by H2-Pharma LLC, and CMS classifies it as a generic product.